Temocillin revived

Livermore, David M. ORCID: https://orcid.org/0000-0002-9856-3703 and Tulkens, Paul M. (2008) Temocillin revived. Journal of Antimicrobial Chemotherapy, 63 (2). pp. 243-245. ISSN 0305-7453

Full text not available from this repository. (Request a copy)


Resistance in Gram-negative pathogens is an increasing concern, with carbapenems often appearing as the only acceptable treatment option in serious infections. Reviving older compounds that have fallen into disuse may help to alleviate this burden. Temocillin (6-a-methoxy-ticarcillin) is resistant to most if not all classical and extended-spectrum ß-lactamases and to AmpC enzymes. It is also chemically stable, allowing administration by continuous infusion. Pharmacokinetic/pharmacodynamic analysis, aided by Monte-Carlo simulations, suggests a breakpoint of 8 mg/L for the registered maximum dosage of 4 g daily. Temocillin's weaknesses, explaining its limited previous use, are a lack of activity against Gram-positive organisms, anaerobes and Pseudomonas. In settings where these are unlikely or are covered by other agents, temocillin may be useful, potentially ‘sparing’ carbapenems and having little apparent potential to select for Clostridium difficile.

Item Type: Article
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023)
Faculty of Medicine and Health Sciences > Research Groups > Epidemiology and Public Health
Depositing User: Rhiannon Harvey
Date Deposited: 05 Jul 2011 11:17
Last Modified: 24 Oct 2022 00:44
URI: https://ueaeprints.uea.ac.uk/id/eprint/33355
DOI: 10.1093/jac/dkn511

Actions (login required)

View Item View Item